Form 8-K · Current Report · Filed 2024-10-31
IQVIA Reports Q3 2024 Financial Results and Updates Guidance
IQVIA Holdings Inc. reported its third-quarter 2024 financial results on October 31, 2024, revealing a revenue of $3,896 million, a GAAP Net Income of $285 million, and Adjusted EBITDA of $939 million. The company's Technology & Analytics Solutions (TAS) revenue increased by 8.6% year-over-year, while Research & Development Solutions (R&DS) revenue grew by 1.9%. IQVIA also updated its full-year 2024 guidance due to delays in two fast-burning mega trials, now expecting revenue between $15,350 million and $15,400 million, Adjusted EBITDA between $3,675 million and $3,700 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.20.
- Filer
- Iqvia Holdings Inc. IQV · NYSE
- Filed
- Accession
- 0001478242-24-000113
- CIK
- 0001478242
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$216.04
Next session
-3.2%
Since filing
+8.8%
Latest close
$235.02
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IQV reporting the same item, with the next session's move:
Exhibits (1)
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Never miss another IQV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.